Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover extension study of pelacarsen in participants with ASCVD and elevated lipoprotein(a)
CTR20262739Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in atherosclerotic disease, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Started May 2025; status: terminated.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20262739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262739.